8-K: Chemed Corporation Reports Strong Second Quarter Growth Driven by VITAS Healthcare

Chemed Corporation's second quarter results show significant growth in its VITAS Healthcare segment, offsetting a decline in Roto-Rooter revenue.

Summary

• Chemed Corporation reported its financial results for the second quarter ended June 30, 2024.
• Consolidated revenue increased by 7.6% to $595.9 million.
• GAAP diluted earnings per share (EPS) rose by 32.5% to $4.65.
• Adjusted diluted EPS increased by 34.1% to $5.47.
• The VITAS segment saw a 16.7% increase in net patient revenue, reaching $374.6 million.
• VITAS' average daily census (ADC) increased by 14.4% to 21,036.
• VITAS' admissions increased by 11.0% to 17,334.
• VITAS' net income, excluding certain items, increased by 91.1% to $49.9 million.
• VITAS' adjusted EBITDA, excluding Medicare Cap, increased by 77.0% to $67.0 million.
• VITAS' adjusted EBITDA margin, excluding Medicare Cap, increased by 613 basis points to 17.8%.
• The Roto-Rooter segment experienced a 5.0% decrease in revenue to $221.3 million.
• Roto-Rooter's net income, excluding certain items, decreased by 8.1% to $42.4 million.
• Roto-Rooter's adjusted EBITDA decreased by 9.2% to $59.8 million.
• Roto-Rooter's adjusted EBITDA margin decreased by 126 basis points to 27.0%.

Sentiment

Score: 8

Explanation: The document presents a generally positive outlook with strong growth in the VITAS segment and an upward revision of full-year guidance. However, the decline in Roto-Rooter's performance and the inherent risks in the healthcare and home services industries temper the overall sentiment.

Positives

• Chemed's overall financial performance was strong, with significant increases in revenue and earnings per share.
• The VITAS segment showed substantial growth in revenue, patient census, and profitability.
• The acquisition of Covenant Health's hospice assets is expected to contribute significantly to VITAS's revenue and earnings.
• VITAS was awarded a Certificate of Need to begin hospice operations in Pasco County, Florida, expanding its service area.
• Chemed has a strong cash position with $222.9 million in cash and no debt.
• The company has a significant undrawn borrowing capacity of $404.8 million under its credit agreement.
• The company has revised its full-year 2024 earnings per diluted share guidance upwards.
• VITAS's gross margin, excluding Medicare Cap, increased significantly to 24.1% from 18.7% in the prior year quarter.

Negatives

• Roto-Rooter experienced a decline in revenue and profitability in the second quarter.
• Roto-Rooter's commercial and residential revenue both decreased.
• Roto-Rooter's adjusted EBITDA margin decreased by 126 basis points.
• The company's Roto-Rooter segment is forecasted to have a revenue decline for the full year 2024.

Risks

• Changes in regulations governing the hospice care or plumbing and drain cleaning industries could impact the company.
• Periodic changes in reimbursement levels and procedures under Medicare and Medicaid programs could affect revenue.
• Difficulties in predicting patient length of stay and estimating potential Medicare reimbursement obligations could impact financial results.
• The current shortage of qualified nurses, other healthcare professionals, and licensed plumbing and drain cleaning technicians could affect operations.
• The company's dependence on patient referral sources could pose a risk to its growth strategy.
• The company faces challenges inherent in its growth strategy.

Future Outlook

Chemed has revised its full-year 2024 earnings per diluted share guidance upwards to a range of $23.55 to $23.80. VITAS revenue is estimated to increase 16.3% to 17.3% and ADC is estimated to increase 13.3% to 14.4%. Roto-Rooter is forecasted to have a 4.0% to 5.0% revenue decline in 2024.

Management Comments

• Chemed uses certain non-GAAP metrics such as EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted earnings per share, to provide additional context and perspective to reported operational results.
• Chemed's management uses EBITDA, Adjusted EBITDA and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies.

Industry Context

The results reflect the ongoing demand for end-of-life care services, as evidenced by the strong performance of VITAS. The decline in Roto-Rooter's revenue may indicate a broader trend in the plumbing and drain cleaning industry or specific challenges faced by the company in this sector. The acquisition of Covenant Health's hospice assets is a strategic move to expand VITAS's market presence and capitalize on the growing demand for hospice services.

Comparison to Industry Standards

• The VITAS segment's 16.7% revenue growth and 14.4% ADC increase are strong compared to industry averages for hospice care providers, which typically see single-digit growth.
• The adjusted EBITDA margin increase of 613 basis points for VITAS is significantly above industry benchmarks, indicating improved operational efficiency and cost management.
• Roto-Rooter's 5.0% revenue decline contrasts with the performance of some other home services companies, which have seen growth in the same period, suggesting potential competitive pressures or market-specific challenges.
• The company's overall adjusted diluted EPS growth of 34.1% is well above the average for companies in the healthcare and home services sectors, indicating strong financial performance.
• The acquisition of Covenant Health's hospice assets for $85.0 million is a significant investment, and its contribution of $8.2 million to $8.7 million in revenue in the second quarter is a positive sign for the return on investment.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and upward revision of guidance.
• Employees of VITAS may benefit from the company's growth and expansion.
• Customers of VITAS will continue to receive end-of-life care services.
• Suppliers of VITAS will likely see increased demand for their products and services.
• Creditors of Chemed will be reassured by the company's strong financial position and cash flow.

Next Steps

• Chemed will host a conference call and webcast on July 25, 2024, to discuss the quarterly results and provide a business update.
• The company will continue to integrate the acquired Covenant Health hospice assets into its VITAS operations.
• Chemed will continue to monitor and manage the performance of its Roto-Rooter segment.

Key Dates

Keywords

Chemed, VITAS Healthcare, Roto-Rooter, Hospice, Plumbing, Drain Cleaning, Healthcare, EBITDA, Revenue, Earnings Per Share, Medicare, Acquisition, Financial Results